3-spiro-7-hydroxamic acid tetralins as HDAC inhibitors
US9630922B2 · kind B2 · utility
49Cited by
3References
33Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 15, 2016 |
| Grant date | Apr 25, 2017 |
| Priority date | — |
| Expiry date | Apr 15, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.